Yahoo Finance • 2 months ago

Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer

Myriad Genetics, Inc. SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research collaborations to study the us... Full story

Yahoo Finance • 3 months ago

Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Myriad Genetics, Inc. SALT LAKE CITY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issu... Full story

Yahoo Finance • 4 months ago

Insider Sale at Myriad Genetics Inc (MYGN): SVP, Chief of Staff Margaret Ancona Sells Shares

On August 21, 2024, Margaret Ancona, Senior Vice President, Chief of Staff at Myriad Genetics Inc (NASDAQ:MYGN), executed a sale of 11,538 shares of the company. Following this transaction, the insider now owns 79,366 shares of Myriad Gene... Full story

Yahoo Finance • 4 months ago

Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

Myriad Genetics, Inc. SALT LAKE CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in two upcoming investor... Full story

Yahoo Finance • 7 months ago

Insider Sale: Director Lee Newcomer Sells 6,200 Shares of Myriad Genetics Inc (MYGN)

On May 13, 2024, Director Lee Newcomer sold 6,200 shares of Myriad Genetics Inc (NASDAQ:MYGN) as reported in a recent SEC Filing. The transaction occurred at a price of $25.3 per share. Warning! GuruFocus has detected 4 Warning Signs with... Full story

Yahoo Finance • 8 months ago

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

Myriad Genetics, Inc. Fewer patients were prescribed medications with gene-drug interactions after taking the GeneSight test SALT LAKE CITY, April 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic tes... Full story

Yahoo Finance • last year

Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents

SALT LAKE CITY, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has delivered results to one million consumers with its SneakPeek® Early Gend... Full story

Yahoo Finance • last year

Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers

SALT LAKE CITY and FREMONT, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc., a leader in advanced genomics for precision oncology, (... Full story

Yahoo Finance • last year

Myriad Genetics to Participate in Stephens Annual Investment Conference

SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in the Stephens Annual Investment Conference... Full story

Yahoo Finance • last year

Myriad Genetics Announces Pricing of Upsized Offering of Common Stock

SALT LAKE CITY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (the “Company” or “Myriad Genetics”), a leader in genetic testing and precision medicine, today announced the pricing of an upsized underwritten publi... Full story

Yahoo Finance • last year

Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock

SALT LAKE CITY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (the “Company” or “Myriad Genetics”), a leader in genetic testing and precision medicine, today announced that it plans to make a public offering of $... Full story

Yahoo Finance • last year

Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance

Myriad Genetics, Inc. Highlights: Third quarter testing volume grew 18% year-over-year, excluding contributions from the SneakPeek® Early Gender DNA Test, the fifth consecutive quarter of double-digit year-over-year growth. In the third... Full story

Yahoo Finance • last year

Myriad Genetics Appoints Sam Raha as Chief Operating Officer

SALT LAKE CITY, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Sam Raha as Chief Operating Officer (COO), effective December... Full story

Yahoo Finance • last year

QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer

Partnership covers development of lab-developed and distributable kit-based companion diagnostic testsCombined strengths in assay development, clinical testing, and regulatory approvals offers pharma partners comprehensive global companion... Full story

Yahoo Finance • last year

QIAGEN und Myriad Genetics schließen Partnerschaft und treiben Entwicklung von Begleitdiagnostika für Krebs voran

Partnerschaft umfasst die Entwicklung von im Labor entwickelten (LDT) und vertriebsfähigen diagnostischen Begleittests auf Kit-Basis // Vereinte Stärken in den Bereichen Assay-Entwicklung, klinische Tests und regulatorische Zulassungen bie... Full story

Yahoo Finance • last year

New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood

SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a nationwide survey revealing breast density and family health hist... Full story

Yahoo Finance • last year

Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials

SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic partnership with Illumina Inc. (NASDAQ: ILMN... Full story

Yahoo Finance • last year

Myriad Genetics Issues 2022 Environmental, Social and Governance Report

SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its second annual Environmental, Social and Governance report, highlighting key... Full story

Yahoo Finance • last year

Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer

SALT LAKE CITY, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) to study the... Full story

Yahoo Finance • last year

Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work

SALT LAKE CITY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Great Place To Work® and Fortune magazine have named Myriad Genetics to the 2023... Full story